Ready, set, slow down
The first new TB drugs in decades have received conditional regulatory approval, but remain largely out of the reach of patients. Re-purposed medicines are showing effectiveness against TB, but aren't registered for that purpose, which hinders their use in treating TB patients.
High prices are another significant barrier to accessing promising new and re-purposed drugs. In this fact sheet, MSF looks at accessibility of five key drugs: bedaquiline, delamanid, imipenem/cilastatin, clofazimine and linezolid.
Additional publications in the DR-TB Drugs Under the Microscope report series are available here.
Learn more about MSF’s work to improve access to lifesaving TB treatment.
Read a related Feature Story here.